
CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary
Keywords: AC; acenocoumarol; VKA; vitamin K antagonist; NOACs; novel oral anticoagulants; OEP; Hungarian acronym, National Health Insurance Fund of Hungary; INR; International Normalized Ratio; CYP2C9; Cytochrome P450 2C9; VKORC1; Vitamin K Epoxide Reductase Comple